Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by symmetrical polyarticular
synovitis of the diarthrodial joints. Several proinflammatory
cytokines derived from both infiltrating inflammatory cells and activated resident cells within the RA joint play a fundamental role in the processes that cause
inflammation. However, anticytokine treatment is beneficial but not curative, the effects are only partial, and nonresponses are common. Therefore, an effort has been made to identify other key regulators of
inflammation in articular structures to develop new
therapies to suppress synovial
inflammation and joint destruction in RA. Adipose tissue-derived
angiopoietin-like protein 2 (Angptl2) activates an inflammatory cascade in endothelial cells and induces chemotaxis of monocytes/macrophages in
obesity, resulting in initiation and propagation of
inflammation within adipose tissues and
obesity-related
metabolic diseases. Angptl2
mRNA and
protein are abundantly expressed in hyperplastic rheumatoid synovium of RA patients, especially in fibroblast-like and macrophage-like synoviocytes, but not in B and T lymphocytes. Angptl2 concentration in joints of RA patients was also significantly increased in comparison with patients with
osteoarthritis, which in comparison with RA represents a significantly lower inflammatory grade form of
arthritis. Notably, Angptl2 promoted increased chemotactic activities of CD14+CD16- monocytes from synovial fluid of RA patients. Therefore, Angptl2 acts as an important rheumatoid synovium-derived inflammatory mediator in RA pathogenesis.